Coronavirus lung damage can be relieved by hemp extract cannabidiol, or CBD, which can counter much of the inflammation caused by COVID Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019
Study shows CBD reduces coronavirus lung damage
Coronavirus lung damage can be relieved by hemp extract cannabidiol, or CBD, which can counter much of the inflammation caused by COVID
Research published in the Medical Journal of Australia explains that COVID-19 is a combination of viral pneumonia and acute respiratory distress syndrome or ARDS. Because of the latter, it can cause serious coronavirus lung damage.
Yale Medicine adds that COVID-related ARDS typically “sets in” approximately eight days after symptoms first appear. Additionally, certain people have a higher risk of developing ARDS with this particular coronavirus. This includes those who are older and people with chronic health conditions such as diabetes and high blood pressure.
While many potential therapeutics are being explored to help ease coronavirus lung damage, one study reveals that the hemp extract cannabidiol — which is better known as CBD — may play an important role in this process.
CBD and its impact on coronavirus lung damage
This research involved 30 adult male mice that were split into three groups. Two of the groups received daily intranasal administration of polyinosinic:polycytidylic acid (Poly I:C) for three consecutive days to mimic ARDS, with one of these groups also receiving CBD treatments every other day until three doses were administered. The third group received sterile saline intranasally and served as a control.
On day nine of the study, all of the mice were euthanized and their lung tissue was harvested by a blind investigator. A flow cytometry analysis was conducted and revealed that the mice that were administered Poly I:C only had lower T cell frequency, elevated neutrophils, and a reduction of apelin. The mice that were also treated with CBD showed different results. Namely, they had more normal levels of T cells and neutrophils and their apelin was enhanced.
Based on these findings, researchers concluded that CBD helped improve lung structure and exerted “a potent anti-inflammatory effect.” They further noted that it worked by helping to protect the endocannabinoid system, as evidenced by its impact on apelin. The full study was published in the Journal of Cellular and Molecular Medicine on Oct. 15, 2020.
Understanding apelin and disease
Apelin is one of two peptic ligands within the apelinergic system. An article published by the Canadian Institutes of Health Research in the journal Comprehensive Physiology shares that the apelinergic system has a number of important functions. Among them are assisting with vasodilation, modulating glucose and insulin, and aiding in the development of the cardiovascular system.
Because this system interacts with all of these functions, it has also been linked to a variety of diseases. This includes chronic heart failure, diabetes, and obesity. There also appears to be a connection between the apelinergic system and HIV. Thus, targeting this system may hold the key to treating a variety of major health conditions.
Treatment with CBD is not so simple
In a Letter to the Editor published March 31, 2020, by the Research in Social and Administrative Pharmacy journal, Joshua Brown from the University of Florida College of Pharmacy warns that CBD “has complex pharmacological properties.” Thus, taking CBD doesn’t always provide the desired effect.
Brown points to a study involving Epidiolex, the CBD-containing medication approved by the U.S. Food and Drug Administration to treat serious seizure disorders. Brown says that in this particular study, participants receiving CBD had higher rates of infection — both viral and pneumonia — than those receiving a placebo treatment.
Brown does concede that the average consumer will likely consume lower doses of CBD than contained in this anti-seizure medication. However, those using medical cannabis may consume doses similar to those found in Epidiolex. This could potentially put them at greater risk of infection instead of providing a protective effect.
More research is needed
In the end, more research is needed to fully understand the effect of CBD on COVID-19, coronavirus lung damage, and infection in general. While some studies show promising results, others reveal areas where more information is needed to provide patients the best advice.
In the meantime, educating patients on the potential benefits and risks is critical to helping them make the best decision possible given their health and situation. Discussing dosing is important as well, especially as it relates to the amount of CBD available in some over-the-counter products versus the amount of CBD ingested when using medical marijuana. Starting with lower doses enables patients to better monitor their response to this hemp extract.
Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019
We read with great interest the recent opinion by Nagarkatti et al. (2020), highlighting a potential role of cannabinoids in the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19. In particular, based on their previous studies evaluating the effect of THC in ARDS animal models, they focused the attention on the cannabinoid receptors targeting to control the hyperimmune response in severe COVID-19. Although cannabinoids and CBD in particular show an interesting potential, important issues concerning this therapeutics must be considered.
In recent months, the pressing need for effective treatments to counteract the spread of the COVID-19 pandemic dictated the development of new therapeutic approaches to handle or possibly prevent the complications of SARS-CoV-2 infections as a worldwide priority. Clinical profiles of COVID-19 patients range from asymptomatic infection to severe pneumonia with multisystem failure, the leading cause of mortality. In patients with severe disease, the occurrence of cytokine storm and a state of hyperinflammation led to acute respiratory distress syndrome (ARDS) (Lotfi and Rezaei, 2020). As Nagarkatti and colleagues (2020) highlighted, the potential use of cannabinoids in COVID-19 has been suggested for their immunomodulatory and anti-inflammatory properties, but not for the direct antiviral activity. Several authors focused the attention on the nonpsychoactive CBD as adjuvant in SARS-CoV-2 therapy. Recently, for the first time, it has been reported that CBD is able to reduce pro-inflammatory cytokine levels ameliorating symptoms of ARDS induced in a murine model (Khodadadi et al., 2020). Moreover, CBD seems to down-regulate the expression of ACE2 and TMPRSS2, two receptors exploited by SARS-CoV-2 to enter the cells (Wang et al., 2020). However, further studies to support CBD-mediated regulation of ACE2 and TMPRSS2 are needed.
Despite the encouraging potential of CBD, in our opinion, the first issue to consider is that, to date, there are no clinical data about the optimal anti-inflammatory dose and regimen of CBD in patients. Our knowledge about CBD use in patients comes mainly from few clinical studies evaluating the safety and efficacy of CBD as oral solution in the treatment of serious seizure disorders. The results from these studies highlighted that in comparison with other drugs employed for the treatment of seizure disorders, CBD has an overall safe profile, generally showing mild/moderate adverse effects (AEs). However, although with a low incidence, serious CBD AEs were registered (Brown and Winterstein, 2019; Huestis et al., 2019; Chesney et al., 2020; Dos Santos et al., 2020), some of which deserve particular caution in COVID-19 patients. The CBD-mediated impairment of immune response increases the risk of pneumonia or viral infection. Thus, particular attention must be paid for patients receiving immunosuppressive therapy, as some SARS-CoV-2 patients (Brown and Winterstein, 2019). Most importantly, it was observed that increased transaminases levels (ALT and AST) and hepatic injuries occur in CBD-treated patients who are chronically exposed to antiepileptic drugs, probably due to the multiple drug–drug interactions of CBD (Brown and Winterstein, 2019; Dos Santos et al., 2020).
CBD influences the principal enzymes (e.g., CYP450-3A4, -2C19, and UGTs) responsible for biotransformation of a wide range of drugs, thus potentially having impact on their pharmacokinetics and pharmacodynamics (Brown and Winterstein, 2019). The hypothetic drug–drug interactions of THC and CBD with the drugs currently used in therapeutic protocols for COVID-19, mainly antiviral and immunosuppressive drugs, have been analyzed (Land et al., 2020). However, the clinical profiles of frail patients infected by COVID-19 must be considered. Nowadays, the majority of patients included in CBD clinical trials are children or young adults. ARDS arises in severe COVID-19, and it is now clear that advanced age and several comorbidities including diabetes, hypertension, obesity and cardiovascular diseases are associated with disease severity, and predispose to a worse prognosis (Lotfi and Rezaei, 2020). This implies that with high probability, the COVID-19 patients with ARDS are under chronic therapies to treat their comorbidities. In this frame, we need to take into account the potential interaction of CBD with therapeutics like antiplatelet, antiarrhythmic, antihypertensive, or lipid-lowering drugs like statins, some of which are metabolized by CYP450 and/or UGTs (Brown and Winterstein, 2019), to avoid the worsening of liver and kidney injuries in COVID-19 patients (Lotfi and Rezaei, 2020).
Last but not least, it is reported that to exert their action, some cannabinoids require membrane lipid rafts integrity (Sarnataro et al., 2006), where cannabinoid receptors are localized. To produce its proapoptotic effect in murine primary microglial cells, CBD induces a lipid rafts coalescence, an event specifically reverted by the cholesterol-depleting agent methyl-β-cyclodextrin (Wu et al., 2012), suggesting the key role of lipid rafts in CBD signaling. Even if the anti-inflammatory action of CBD seems to be cannabinoid receptor independent and considering that ACE2 receptor reside into lipid rafts, further investigations are needed to evaluate the potential impact of CBD on SARS-CoV-2–host cell interaction.
The current global emergency dictates the identification of therapeutics suitable to counteract the COVID-19 infection. CBD shows an interesting potential, but it is clear that further studies are required to corroborate this hypothesis, encompassing a clinical evaluation of risks and benefits of CBD use in SARS-CoV-2 patients.
MP and DF designed the General Commentary and drafted the manuscript; CP contributed to the preparation of the manuscript; MB and PG critically revised the manuscript for intellectual content and provided the funding source.
This study was partially supported by Regione Campania—Italy (POR Campania FESR 2014-2020—ASSE I 2020, grant to MB and PG). CP was supported by a PhD Program in Drug Discovery and Development-Department of Pharmacy, the University of Salerno.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Brown, J., and Winterstein, A. (2019). Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Jcm 8 (7), 989. doi:10.3390/jcm8070989
Chesney, E., Oliver, D., Green, A., Sovi, S., Wilson, J., Englund, A., et al. (2020). Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacol. 45, 1799–1806. doi:10.1038/s41386-020-0667-2
Dos Santos, R. G., Guimarães, F. S., Crippa, J. A. S., Hallak, J. E. C., Rossi, G. N., Rocha, J. M., et al. (2020). Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Expert Opin. Drug Metab. Toxicol. 16 (6), 517–526. doi:10.1080/17425255.2020.1754793
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., and Busardò, F. P. (2019). Cannabidiol adverse effects and toxicity. Cn 17 (10), 974–989. doi:10.2174/1570159X17666190603171901
Khodadadi, H., Salles, É. L., Jarrahi, A., Chibane, F., Costigliola, V., Yu, J. C., et al. (2020). Cannabidiol modulates cytokine storm in acute respiratory distress syndrome induced by simulated viral infection using synthetic RNA. Cannabis cannabinoid Res. 5 (3), 197–201. doi:10.1089/can.2020.0043
Land, M. H., MacNair, L., Thomas, B. F., Peters, E. N., and Bonn-Miller, M. O. (2020). Letter to the editor: possible drug-drug interactions between cannabinoids and candidate COVID-19 drugs. Cannabis Cannabinoid Res. 5, 340. doi:10.1089/can.2020.0054
Lotfi, M., and Rezaei, N. (2020). SARS-CoV-2: a comprehensive review from pathogenicity of the virus to clinical consequences. J. Med. Virol. 92 (10), 1864–1874. doi:10.1002/jmv.26123
Nagarkatti, P., Miranda, K., and Nagarkatti, M. (2020). Use of cannabinoids to treat acute respiratory distress syndrome and cytokine storm associated with Coronavirus disease-2019. Front. Pharmacol. 11, 589438. doi:10.3389/fphar.2020.589438
Sarnataro, D., Pisanti, S., Santoro, A., Gazzerro, P., Malfitano, A. M., Laezza, C., et al. (2006). The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol. Pharmacol. 70 (4), 1298–1306. doi:10.1124/mol.106.025601
Wang, B., Kovalchuk, A., Li, D., Rodriguez-Juarez, R., Ilnytskyy, Y., Kovalchuk, I., et al. (2020). In search of preventative strategies: novel high-CBD cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging 12 (22), 22425–22444. doi:10.18632/aging.202225
Wu, H.-Y., Goble, K., Mecha, M., Wang, C.-C., Huang, C.-H., Guaza, C., et al. (2012). Cannabidiol-induced apoptosis in murine microglial cells through lipid raft. Glia 60 (7), 1182–1190. doi:10.1002/glia.22345
Keywords: cannabinoids, cannabidiol, SARS–CoV–2, COVID–19, pneumonia, ARDS
Citation: Bifulco M, Fiore D, Piscopo C, Gazzerro P and Proto MC (2021) Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019. Front. Pharmacol. 12:631646. doi: 10.3389/fphar.2021.631646
Received: 20 November 2020; Accepted: 03 February 2021;
Published: 12 April 2021.
Stefania Tacconelli, University of Studies G. d’Annunzio Chieti and Pescara, Italy
Cristina Maccallini, University of Studies G. d’Annunzio Chieti and Pescara, Italy
Luciano De Petrocellis, Consiglio Nazionale delle Ricerche (CNR), Italy
Copyright © 2021 Bifulco, Fiore, Piscopo, Gazzerro and Proto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.